Table 1 Baseline characteristics.
Training dataset | Test dataset | p | |
|---|---|---|---|
N = 226 | N = 75 | ||
Age | 44.4 | 47.8 | |
KPS | 78.5 | 83.3 | |
ECOG | 1.24 | 1.21 | |
Disease stage | 0.98 | ||
I | 25 (11% ) | 9 (12%) | |
II | 93 (41%) | 29 (39%) | |
III | 74 (33%) | 25 (33%) | |
IV | 34 (15%) | 12 (16%) | |
HR | 0.97 | ||
Positive | 105 (46%) | 34 (45%) | |
Negative | 121 (54%) | 41 (55%) | |
Multi Extracranial Metastasis | 0.24 | ||
Yes | 124 (0.55) | 47 (0.63) | |
No | 102 (0.45) | 28 (0.37) | |
Multi Brain Metastasis | 0.46 | ||
Yes | 69 (31%) | 27 (36%) | |
No | 157 (69%) | 48 (64%) | |
Surgery | 0.22 | ||
Yes | 20 (9%) | 11 (15%) | |
No | 206 (91%) | 64 (85%) | |
Radiotherapy | 0.41 | ||
Yes | 181 (80%) | 56 (75%) | |
No | 45 (20%) | 19 (25%) | |
Trastuzumab | 0.93 | ||
Yes | 151 (67%) | 49 (65%) | |
No | 75 (33%) | 26 (35%) | |
Trastuzumab + Pertuzumab | 0.23 | ||
Yes | 53 (23%) | 12 (16%) | |
No | 173 (77%) | 63 (84%) | |
Pyrotinib | 0.001 | ||
Yes | 92 (41%) | 49 (65%) | |
No | 134 (59%) | 26 (35%) | |
T-DM1 | 0.83 | ||
Yes | 26 (12%) | 10 (13%) | |
No | 200 (88%) | 65 (87%) | |
